- Trials with a EudraCT protocol (10)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10 result(s) found for: β-catenin.
Displaying page 1 of 1.
EudraCT Number: 2012-000155-14 | Sponsor Protocol Number: V2.0 | Start Date*: 2013-12-13 |
Sponsor Name:Med. Universität Wien, Universitätsklinik für Innere Medizin II | ||
Full Title: In vivo assessment of the molecular mechanism of inhaled combination of beclomethasone and formoterol on cell differentiation factors and airway remodelling in COPD | ||
Medical condition: COPD | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-022410-11 | Sponsor Protocol Number: 33606.068.10 | Start Date*: 2011-07-18 |
Sponsor Name:MUMC | ||
Full Title: Topical Diclofenac and Vitamin D3 to treat Basal Cell Carcinoma | ||
Medical condition: Basal Cell Carcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004868-30 | Sponsor Protocol Number: PNET5MB | Start Date*: 2013-10-31 | |||||||||||
Sponsor Name:University Medical Center Hamburg-Eppendorf | |||||||||||||
Full Title: AN INTERNATIONAL PROSPECTIVE TRIAL ON MEDULLOBLASTOMA (MB) IN CHILDREN OLDER THAN 3 TO 5 YEARS WITH WNT BIOLOGICAL PROFILE (PNET 5 MB – LR and PNET 5 MB – WNT-HR), AVERAGE-RISK BIOLOGICAL PROFILE (... | |||||||||||||
Medical condition: Children with medulloblastoma. Medulloblastoma is a highly cellular malignant embryonal neoplasm. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) FI (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) GB (GB - no longer in EU/EEA) AT (Ongoing) NO (Completed) CZ (Trial now transitioned) NL (Trial now transitioned) DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001815-29 | Sponsor Protocol Number: MDL_2011_36557 | Start Date*: 2011-11-11 | |||||||||||
Sponsor Name:UMC Utrecht | |||||||||||||
Full Title: Chemopreventive effects of mesalazine in patients at high risk of recurrent (nonfamilial) colorectal adenomas | |||||||||||||
Medical condition: sporadic colorectal adenomas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002464-14 | Sponsor Protocol Number: GEIS-39 | Start Date*: 2017-03-02 |
Sponsor Name:Grupo Español de Investigación en Sarcomas (GEIS) | ||
Full Title: Phase II trial of nab-paclitaxel for the treatment of desmoid tumors and multiply relapsed/refractory desmoplastic small round cell tumors and Ewing sarcoma | ||
Medical condition: Cohort 1: Subjects with desmoid tumor Cohort 2: Subjects with desmoplastic small round cell tumor or Ewing sarcoma | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000613-32 | Sponsor Protocol Number: STEMNESS-CRC | Start Date*: 2020-07-24 | |||||||||||
Sponsor Name:1Globe Health Institute | |||||||||||||
Full Title: A Phase III, Randomized, Open-Label Clinical Study of Napabucasin in Combination with FOLFIRI and Best Supportive Care (BSC) Versus Napabucasin plus BSC (or BSC alone) in Adult Patients with Previo... | |||||||||||||
Medical condition: Histologically confirmed adenocarcinoma of the colon or rectum that is metastatic. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002553-35 | Sponsor Protocol Number: STEMNESS-PANC | Start Date*: 2022-02-21 | |||||||||||
Sponsor Name:1Globe Health Institute | |||||||||||||
Full Title: A Phase II/III Randomized, Open-Label Clinical Study of Napabucasin in Combination with Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Metastatic Pancreatic Cancer Following Chemothera... | |||||||||||||
Medical condition: Histologically or cytologically confirmed advanced pancreatic adenocarcinoma that is metastatic. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002468-41 | Sponsor Protocol Number: Dial-1 | Start Date*: 2018-06-21 | |||||||||||
Sponsor Name:University Medical Center of the Johannes Gutenberg- University Mainz | |||||||||||||
Full Title: A phase I/II multicenter, open-label Study of DKN-01 to investigate the anti-tumor activity and safety of DKN-01 in Patients with Hepatocellular Carcinoma and WNT signaling Alterations | |||||||||||||
Medical condition: Hepatocellular Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000774-18 | Sponsor Protocol Number: BBI608-336 | Start Date*: 2015-01-26 | |||||||||||
Sponsor Name:Boston Biomedical, Inc. | |||||||||||||
Full Title: A Phase III Randomized, Double-Blind, Placebo-Controlled Clinical Trial of BBI608 plus Weekly Paclitaxel vs. Placebo plus Weekly Paclitaxel in Adult Patients with Advanced, Previously Treated Gastr... | |||||||||||||
Medical condition: Advanced (metastatic or locally advanced and unresectable), gastric or gastroesophageal junction (GEJ) adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) LT (Prematurely Ended) HU (Prematurely Ended) DE (Prematurely Ended) PL (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) EE (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001627-31 | Sponsor Protocol Number: CanStem303C | Start Date*: 2016-12-20 | |||||||||||
Sponsor Name:Sumitomo Dainippon Pharma Oncology, Inc. | |||||||||||||
Full Title: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) | |||||||||||||
Medical condition: Histologically confirmed adenocarcinoma of the colon or rectum that is metastatic (Stage IV). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) BE (Completed) CZ (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
